Sernova Biotherapeutics Inc (ETR:PSH0)
Germany
· Delayed Price · Currency is EUR 0.0800
-0.0195 (-19.60%)
At close: Jun 24, 2025, 5:30 PM CET
Sernova Biotherapeutics Employees
Sernova Biotherapeutics had 17 employees as of October 31, 2024.
Employees
17
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
€876,174
Market Cap
34.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Allianz SE | 156,626 |
| Rheinmetall AG | 28,539 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Siemens Energy AG | 98,000 |
| Siemens Healthineers AG | 72,000 |
Sernova Biotherapeutics News
- 22 days ago - Sernova Appoints Jonathan Rigby as Interim Chair - GlobeNewsWire
- 4 weeks ago - Chair of Sernova Biotherapeutics Resigns - GlobeNewsWire
- 4 weeks ago - Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D - GlobeNewsWire